MMP2 and prostate carcinoma: Furthermore, ibrutinib decreased the synthesis of matrix metalloproteinases-2 and -9 (MMP-2 and MMP-9)—endopeptidases, of which overexpression is associated with increased invasiveness and severity of prostate cancer [96,112,113].